Assignee: Bristol-Myers Squibb Company

Location: Princeton, NJ
No. of patents: 1981

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

Number	Title	Issue Date
8445676	Pyrrolotriazine kinase inhibitors The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as Jak2 and CK2, thereby making them useful as an...	05/21/2013
8445497	Compounds for the treatment of hepatitis C The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. ...	05/21/2013
8445494	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine The present disclosure generally relates to a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as wel...	05/21/2013
8445490	Compounds for the treatment of hepatitis C The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV...	05/21/2013
8436168	Methods of making HIV attachment inhibitor prodrug compound and intermediates A method for making the compound of Formula I: is set forth using alkylation, amidation, chlorination and phosphate installation procedures. ...	05/07/2013
8436158	Antibodies to IL-6 and their uses Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such ...	05/07/2013
8436000	Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are CRF receptor antagonists and may be useful for treating disorders associated with abnormal CRF levels or aberrant f...	05/07/2013
8431568	Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors The disclosure provides compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.	04/30/2013
RE44186	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula where x is 0 or 1 and y is 0 or 1 (provided that x=1 when y=0 and x=0 when y=1); ...	04/30/2013
8426414	Modulators of G protein-coupled receptor 88 The present disclosure is generally directed to compounds which can modulate G-protein coupled receptor 88, compositions comprising such compounds, and methods for modulating G-protein coupled receptor 88. ...	04/23/2013
8425904	Human antibodies that bind mesothelin, and uses thereof The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of ...	04/23/2013
8420830	Macrocyclic factor VIIa inhibitors useful as anticoagulants The present invention relates generally to novel macrocycles of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1	04/16/2013
8420811	Tetrahydroisoquinolines and intermediates therefor Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and a crystalline form of 6-[(4S)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]...	04/16/2013
8420365	11βhydroxysteroid dehydrogenase type 1 The invention provides gene-targeted non-human animals comprising a genetically modified 11βHSD1 gene encodes a mutant 11βHSD1 polypeptide which is modulated by human 11βHSD1 modulating compounds. The invention further provides cells expressing mutant 11βHSD1 an...	04/16/2013
8420098	Fibronectin based scaffold domain proteins that bind to PCSK9 The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related dis...	04/16/2013
8415386	Azolopyrrolone melanin concentrating hormone receptor-1 antagonists The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein all of the variables are defined herein. ...	04/09/2013
8415374	Combinations of hepatitis C virus inhibitors The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combin...	04/09/2013
8415367	Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators Novel compounds of structure Formula I: or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein n1, R1, R2, R3 and R4 are defined herei...	04/09/2013
8415340	Triazine kinase inhibitors The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents. ...	04/09/2013
8410155	Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors The present invention provides compounds of Formula (I) or (II): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L1, R3, R4, R...	04/02/2013
8410139	Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity The present application describes prodrugs of the compound of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof. In addition, methods of treating and preventing inflammatory diseases such as asthma ...	04/02/2013
8410128	Triazolopyridine compounds useful as kinase inhibitors A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of p38 kinase....	04/02/2013
8404896	N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases Compounds of formula (Ia) and (Ib), wherein A, B, C, R1and R14 are described herein. ...	03/26/2013
8404741	Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase The present disclosure is generally directed to compounds that can inhibit DAGLα and/or β activity, compositions comprising such compounds, and methods for inhibiting DAGLα and/or β activity. ...	03/26/2013
8404689	Heterocyclic amide compounds useful as kinase inhibitors A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions asso...	03/26/2013
8399647	Alpha5-beta1 antibodies and their uses The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin α5β1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclos...	03/19/2013
8399623	Human antibodies that bind mesothelin, and uses thereof The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of ...	03/19/2013
8399451	Heterocyclic compounds Disclosed are compounds of Formula (I) or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is Q is a substituted 5-membered mono...	03/19/2013
8394968	Hepatitis C virus inhibitors The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infec...	03/12/2013
8394823	Triazolopyridine compounds useful as DGAT1 inhibitors Disclosed are triazolopyridine compounds of the following Formula (I); or stereoisomers or salts thereof. Also, disclosed are methods of using the compound in the treatment of obesity, dyslipidemia, diabetes and atherosclerosis, and to pharmaceutical compositions co...	03/12/2013
8389527	Substituted imidazopyridazines useful as kinase inhibitors The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents. ...	03/05/2013
8389509	Substituted pyrazole compounds Disclosed are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: n is zero or an integer selected from 1 through 4; R1 is cycloalkyl, aryl, heteroaryl, or heterocyclyl, each optional...	03/05/2013
8383812	N-((1R,2S,5R)-5-(-butylamino)-2-((S)-3-(7--butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes The present invention provides a novel antagonist: N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide: or a pharmaceutically acceptable...	02/26/2013
8383779	Human antibodies that bind mesothelin, and uses thereof The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of ...	02/26/2013
8383639	HIV integrase inhibitors The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also enco...	02/26/2013
8383094	Hepatitis C virus inhibitors The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infec...	02/26/2013
8377980	Hepatitis C virus inhibitors The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infec...	02/19/2013
8372847	Pyrazinone modulator of corticotropin-releasing factor receptor activity The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatmen...	02/12/2013
8372837	Pyridone and pyridazone analogues as GPR119 modulators Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R21, T1, T2, T3 and T4 are defined herein, are p...	02/12/2013
8367709	Dipeptide analogs as coagulation factor inhibitors Disclosed are novel dipeptide analogs compounds of Formula (I), (II) or (III): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, or a prodrug thereof, which are inhibitors of factor XIa and/or pl...	02/05/2013

«First «Previous1 2 3 4 5 6 7 8 9 10 11 Next»Last»

PatentStorm

Quotables

PatentStorm News

Assignee: Bristol-Myers Squibb Company